press releases

There are currently no events to display.
Date Title  
10/02/20
European Medicines Agency will evaluate eli-cel MAA under accelerated assessment CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 2, 2020-- bluebird bio, Inc . (Nasdaq: BLUE) today announced that the European Medicines Agency (EMA) accepted the company’s marketing authorization application (MAA) for its
 
09/28/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 28, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the Jefferies Cell Therapy Virtual Summit, Tuesday, October 6 , at 2:00 p.m. ET . To access the live webcast of bluebird bio’s presentation,
 
09/23/20
EMA’s PRIME program designed to optimize development and expedite evaluation of innovative medicines for patients with high unmet need CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 23, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) announced today that its investigational treatment for sickle cell disease
 
09/22/20
FDA set a target action date of March 27, 2021   Ide-cel is the first CAR T cell therapy accepted for regulatory review for multiple myeloma PRINCETON, N.J. , & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 22, 2020-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc .
 
09/02/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 2, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: 2020 Wells Fargo Virtual Healthcare Conference , Thursday, September 10 , at 4:00 pm ET Morgan
 
08/29/20
Long-term results from Phase 2/3 Starbeam study (ALD-102/LTF-304) suggest durability of response post eli-cel with all 20 patients who were free of major functional disabilities (MFDs) at two years (out of 23 evaluable patients) remaining MFD-free through last available follow-up, including all 10
 
08/17/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 17, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that new data from the clinical development program for its investigational elivaldogene autotemcel (eli-cel, Lenti-D™) gene therapy in patients with cerebral adrenoleukodystrophy (CALD), including
 
08/11/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 11, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has appointed Denice Torres to its Board of Directors. “We’re excited to welcome Denice to the Board to help guide bluebird as we reach the next stage in our evolution,” said Nick Leschly ,
 
08/05/20
– First sickle cell patient treated with drug product manufactured with suspension-based lentiviral vector in HGB-206 – – Elivaldogene autotemcel (eli-cel, Lenti-D gene therapy) in cerebral adrenoleukodystrophy (CALD) granted accelerated assessment of Marketing Authorization Application (MAA) from
 
07/31/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 31, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced members of the management team will participate in the Canaccord Genuity 40 th Annual Growth Conference, Wednesday, August 12 , at 10:30 a.m. ET . To access the live webcast of bluebird bio’s
 
07/29/20
BLA submission based on results from pivotal Phase 2 KarMMa study evaluating ide-cel in heavily pre-treated patient population Companies are committed to working with the FDA to rapidly advance ide-cel through the regulatory review process PRINCETON, N.J. , & CAMBRIDGE, Mass.
 
06/12/20
99.5% reduction in annualized rate of vaso-occlusive crises (VOC) and acute chest syndrome (ACS) in Group C patients with a history of VOCs and ACS (n=14) who had at least six months follow-up At up to 24 months, no reports of serious VOC or ACS in Group C patients (n=18) with at least six months
 
06/12/20
89% of evaluable patients (17/19) with transfusion-dependent β-thalassemia who do not have a β 0 /β 0 genotype achieved transfusion independence with 11.9 g/dL median weighted average total hemoglobin (Hb) level in HGB-207 Data from exploratory analyses of HGB-207 show improved markers of blood
 
06/03/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 3, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that, due to the public health and safety concerns related to the novel coronavirus (COVID-19) pandemic, to support the health and well-being of its directors, employees and stockholders, the
 
05/28/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 28, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that the company will host a live webcast to review new data presented at the European Hematology Association (EHA) Annual Meeting on Friday, June 12 at 8:00 am ET .
 
05/18/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 18, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) today announced the pricing of an underwritten public offering of 9,090,910 shares of its common stock at a public offering price of $55.00 per share, before underwriting discounts.
 
05/18/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 18, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has commenced an underwritten public offering of $400 million of its common stock. bluebird bio also intends to grant the underwriters a 30-day option to purchase up to an additional fifteen
 
05/14/20
Presentation of new and updated results from ongoing Phase 1/2 HGB-206 study of LentiGlobin for sickle cell disease will include additional patients treated in the study New and updated data, including analysis of healthy red blood cell production in patients with transfusion-dependent
 
05/13/20
Ide-cel, an investigational CAR T cell therapy for multiple myeloma, met primary endpoint and key secondary endpoints Pivotal study results demonstrated deep and durable responses in a heavily pre-treated and highly refractory patient population PRINCETON, N.J. , & CAMBRIDGE, Mass.
 
05/13/20
Bristol Myers Squibb to host an investor call today at 8:00 a.m. EDT bluebird bio to host an investor call today at 8:45 a.m. EDT PRINCETON, N.J. , & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 13, 2020-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc .
 
05/11/20
- Bristol Myers Squibb to buy out its ex- U.S. milestone and royalty obligations to bluebird bio for $200 million – - Bristol Myers Squibb assumes responsibility for vector manufacturing in ex-US territories – - bluebird to hold conference call and webcast today, May 11, 2020 at 8:00AM ET –
 
05/11/20
- Alignment with FDA on an accelerated regulatory path for LentiGlobin for sickle cell disease based on HGB-206 study with targeted submission in 2H 2021 - - Completed submission with Bristol Myers Squibb of Biologics License Application (BLA) for anti-BCMA CAR T cell therapy idecabtagene vicleucel
 
05/08/20
-Virtual oral presentation will include updated efficacy and safety data from pivotal Phase 2 KarMMa study of ide-cel- -Biologics License Application under review with U.S. Food and Drug Administration (FDA)- CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2020-- bluebird bio, Inc.
 
04/29/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 29, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced it will hold a conference call to discuss first quarter 2020 financial results and business updates on Monday, May 11 at 8:00 am ET . Investors may listen to the call on May 11, 2020 at 8:00 am ET
 
03/31/20
BLA submission includes results from pivotal Phase 2 KarMMa study evaluating ide-cel in a heavily pre-treated patient population with relapsed and refractory multiple myeloma PRINCETON, NJ . & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 31, 2020-- Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc
 
03/26/20
- Company to hold investor conference call today, March 26, 2020 at 8:30 am ET – CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today provided an update in response to the global COVID-19 pandemic. The company has taken steps to ensure the safety of its
 
02/18/20
- First conditional approval of ZYNTEGLO TM (autologous CD34+ cells encoding β A-T87Q -globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β 0 /β 0 genotype in Europe achieved in 2019; Germany launch underway – - Announced positive
 
02/05/20
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will present at the following upcoming investor conferences: 9 th Annual SVB Leerink Global Healthcare Conference , Wednesday, February 26 , at 2:30 p.m.
 
01/13/20
First agreements with statutory health insurances utilize bluebird’s innovative value-based payment model and provide coverage for ZYNTEGLO for up to 50% of patients in Germany First qualified treatment center established at University Hospital of Heidelberg to provide ZYNTEGLO to patients
 

The press releases contained in this section of the website are provided for historical purposes only. The information contained in each press release is accurate only as of the date each press release was originally issued. bluebird bio disavows any obligation to update the information contained in such press releases after the date of their issuance.